Please use this identifier to cite or link to this item:
|Title:||The CarcinoGENOMICS Project: Critical Selection of Model Compounds for the Development of Omics-based in vitro Carcinogenicity Screening Assays|
|Authors:||VINKEN Mathieu; DOKTOROVA Tatyana; ELLINGER-ZIEGELBAUER Heidrun; AHR Hans-Juergen; LOCK Edward; CARMICHAEL Paul; ROGGEN Erwin; VAN DELFT Joost; KLEINJANS Jos; CASTELL Jose; BORT Roque; DONATO Teresa; RYAN Michael; CORVI Raffaella; KEUN Hector; EBBELS Timothy; ATHERSUCH Toby; SANSONE Susanna-Assunta; ROCCA-SERRA Philippe; STIERUM Rob; JENNINGS Paul; PFALLER Walter; GMUENDER Hans; VANHAECKE Tamara; ROGIERS Vera|
|Citation:||MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH vol. 659 p. 202-210|
|Publisher:||ELSEVIER SCIENCE BV|
|Type:||Articles in periodicals and books|
|Abstract:||Recent changes in the European legislation of chemical-related substances have forced the scientific community to speed up the search for alternative methods that could partly or fully replace animal experimentation. The sixth Framework Program project carcinoGENOMICS was specifically raised to develop omics-based in vitro screens for testing the carcinogenic potential of chemical compounds in a pan-European context. This paper provides an in-depth analysis of the complexity of choosing suitable reference compounds used for creating and fine-tuning the in vitro carcinogenicity assays. First, a number of solid criteria for the selection of the model compounds are defined. Secondly, the strategy followed, including resources consulted, is described and the selected compounds are briefly illustrated. Finally, limitations and problems encountered during the selection procedure are discussed. Since selecting an appropriate set of chemicals is a frequent impediment in the early stages of similar research projects, the information provided in this paper might be extremely valuable.|
|JRC Institute:||Institute for Health and Consumer Protection|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.